Kymera Therapeutics, Inc. (KYMR) stock plunged 7.27% in early Thursday trading following the release of its disappointing fourth-quarter results. The biopharmaceutical company reported a wider net loss and lower collaboration revenue compared to the year-ago period, missing analyst estimates.
For the quarter ended December 31, 2024, Kymera Therapeutics posted a net loss of $0.88 per diluted share, significantly worse than the $0.25 loss in the same period a year earlier. The company's collaboration revenue for the quarter came in at $7.4 million, a substantial decrease from $47.9 million in the prior-year quarter. Both figures missed consensus analyst estimates.
The company highlighted its strong cash position of $851 million as of December 31, which is expected to fund operations into mid-2027. However, investors appeared to focus on the disappointing quarterly performance, driving the stock down in pre-market trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。